Biomedicines, Vol. 13, Pages 3117: Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods
Biomedicines, Vol. 13, Pages 3117: Multimodal Prehabilitation for Hernia Repair: Linking Metabolic Modulation and Mechanical Methods Biomedicines doi: 10.3390/biomedicines13123117 Authors: Dan Nicolae Paduraru Alexandru Cosmin Palcau Daniel Ion Razvan Seicaru Background: Abdominal wall hernias represent a significant global surgical burden, with over 20 million repairs performed annually. The convergence of rising obesity and diabetes rates […]
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial – Eli Lilly
Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Lilly’s obesity pill largely maintains weight lost on injectable […]
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly – CNBC
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly CNBC Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management Yahoo Finance A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound. MarketWatch […]
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound – CNBC
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound CNBC Lilly’s orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial Eli Lilly People Are Already Taking This Unapproved New Weight-Loss Drug WIRED Major Weight Loss and Knee-Pain Relief Seen With New […]
2025 in Review: The wellness paradox and the path to healthspan
In 2025, the wellness industry faced contradictions as consumers claimed healthy lifestyles but their use of gut-disrupting drugs told a different story. Despite this, there was a notable shift towards healthspan over lifespan, with increased awareness of aging biomarkers and a demand for personalized health solutions. Technology played a pivotal role, with digital health tools […]
Better Buy in 2026: Novo Nordisk or Intuitive Surgical?
Key Points Novo Nordisk’s new indications for semaglutide and its attractive pipeline could allow it to bounce back. Intuitive Surgical should remain the leader in its niche despite increased competition. Both stocks could be long-term winners, and the choice today might depend on risk tolerance. 10 stocks we like better than Novo Nordisk › Novo […]
Eli Lilly Scores Another Major Win: Time to Buy?
Can anyone stop Eli Lilly (NYSE: LLY)? The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, in addition to having the top approved product in this category, it also has pipeline candidates that outshine […]
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
CagriSema 2.4 mg/2.4 mg is an investigational fixed-dose injectable medicine that combines the novel amylin analogue, cagrilintide, with semaglutide to target complementary obesity-related pathways1,2 In the REDEFINE 1 phase 3 trial, adults with obesity, or overweight with at least one…
Chiptole launches 4-ounce bowl of meat for the Ozempic age
The move signals that we’re about to see a lot more GLP-1-centric menus. Chipotle is officially in its Ozempic era.
Study finds 40% of GLP-1 prescriptions go unfilled: Is cost curbing use of weight loss drugs?
Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, is likely a factor.